Dr Efrat Dotan speaks to ecancer about the GIANT EA2186 trial.

This is a randomized phase II study of gemcitabine/nab-paclitaxel compared with 5 -fluorouracil/leucovorin/liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer.

The study examines older patients with metastatic pancreatic cancer, particularly those over 70.

Patients receive dose-reduced chemotherapy while undergoing comprehensive geriatric assessments.

Results indicate many struggle to start therapy, with survival rates averaging five months.

Key factors like daily living activities and quality of life significantly impact survival.

The study calls for geriatric-specific trials to better address the needs of this vulnerable population.